Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
ALAMEDA, Calif., April 27, 2026 BUSINESS WIRE Infinimmune , a biotechnology company pioneering antibody discovery and design, today announced the appointment of Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy. In this role, Dr. Slavin will lead the development and execution of the company's portfolio strategy, supporting the advancement of Infinimmune's pipeline and the selection of future programs. Prior to joining Infinimmune, Dr. Slavin was an Entrepreneur in Residence at Atlas Venture and Head of Research for a stealth Newco. He previously held senior leadership roles at Kymera Therapeutics, AbbVie, and Boehringer Ingelheim, where he led immunology and inflammation portfolios and advanced multiple programs from target identification through clinical development. He has contributed to the advancement of several therapeutic programs from early discovery through approval, including upadacitinib, risankizumab, and spesolimab. Earlier in his career, Dr. Slavin
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress [Yahoo! Finance]Yahoo! Finance
- FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswire
- Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe AsthmaGlobeNewswire
- Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development CandidateGlobeNewswire
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 4/24/26 - Form 4
- 4/24/26 - Form 4
- 4/22/26 - Form 144
- KYMR's page on the SEC website